Inhibiting IL-6 in Human Multiple Myeloma

Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment

“…Normal osteoclasts are stimulated by cytokines that are produced locally in the bone marrow microenvironment such as IL-6, IL-113, and TNFs [1,21]. Furthermore, IL-6 is produced in large amounts by normal and malignant human osteoblasts [22], by abnormal osteoclasts [23], and by myeloma cells [24], it increases the recruitment of new osteoclasts while it activates directly mature osteoclasts [21] and it is a major growth factor of human MM cells [25]. The significant, concomitant reduction of NTx, IL-6 and paraprotein levels, after the addition of pamidronate in these patients, is possibly due to a direct antitumor effect of pamidronate as it has been demonstrated in several in vitro studies [10,26].…”

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

“…59). These studies led to clinical trials with neutralizing anti-IL-6 antibodies, which showed good antitumor efficacy and a normalization of acute phase activity (115). However, antibody treatment led to massive systemic elevations (approaching mg quantities) in IL-6.…”

Gene expression profiling of human synovial sarcoma cell line (Hs701.T) in response to IL-1β stimulation

“…The reactions were allowed to proceed at 94 °C for 2 min, then 16-21 cycles at 94 °C for 1 min, 55 °C for 1 min, 72 °C for 2 min and fi nal extension at 72 °C for 10 min using the MJ PTC-200 PCR cycler. Due to variations in abundance of different mRNAs, the PCR cycles (24)(25)(26) and different titrations of the RT reaction (equal to 100 ng, 1 µg and 5 µg of total RNA) were performed in triplicate to ensure that the PCR reaction was in the linear range. PCR products were analyzed by electrophoresis on 1.5 % agarose gel, and the intensity of each band was quantifi ed by Kodak 1D software for calculation of the expression ratio.…”